Why Regeneron's Praluent Is Likely To Be Removed From The U.S. Market This Year
March 21, 2016 at 11:08 AM EDT
Chardan Capital’s Gbola Amusa maintained a Sell rating for Regeneron Pharmaceuticals Inc (NASDAQ: REGN), with a price target of ...